Prescribing information

 

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1

ASCVD patients who are struggling to reach their LDL-C goals on statins with or without other lipid-lowering therapy could benefit from inclisiran, provided at scale via a population health programme.1,2

Understanding which of your patients are eligible for the addition of inclisiran, wherever they are on their journey, doesn’t have to be complicated.

To help inform your choice, we have created an infographic that simplifies the current NHS lipid management algorithm,3 adapted to include inclisiran, available for download below. The infographic also presents examples of how inclisiran can fit within existing treatment plans.

 

Let’s introduce you to some patients you are likely to encounter in your practice who could be eligible for inclisiran:

thumbnail image of Paul

Paul*

Is a 67-year-old retired mechanic who enjoys family time, especially playing with his grandchildren. He suffers from diabetes mellitus and hypertension and had a myocardial infarction five years ago. In addition to adhering to a healthy diet, Paul is taking a maximally tolerated statin. With LDL-C levels at 2.8 mmol/L, he still struggles to achieve his goal.

thumbnail image of lisa

Lisa*

Is a 72-year-old retired teacher who enjoys travelling and writing; she has hypothyroidism and suffered from an ischaemic stroke two years ago. Lisa is statin intolerant, and her LDL-C values are at 3.8 mmol/L, despite her efforts to lead a healthier diet and lifestyle and in addition to taking ezetimibe and bempedoic acid

thumbnail image of George

George*

Is an actor who enjoys playing billiards and painting. He has CKD and was hospitalised for unstable angina in the past year. George has made adjustments to his diet and is taking a maximally tolerated dose of statins and ezetimibe, but still struggles to reduce his LDL-C levels to target, which are currently at 3.1 mmol/L.

*Not a real patient.

""

Download the patient identification infographic today,
and identify patients who could benefit from inclisiran

 

Find answers to your questions on inclisiran

hands holding a heart

Delivered at scale via a Novartis and NHS England and NHS Improvement (NHSE&I) population health management programme, inclisiran could benefit many patients with ASCVD who struggle to meet their LDL-C goals on statins with or without other lipid-lowering therapy.1,2 As an HCP-administered therapy, inclisiran offers you oversight of persistence, and the convenience of two maintenance doses a year.*1  

*After an initial dose, inclisiran is administered again at 3 months, followed by every 6 months.1

Q&A speech bubbles icon

To address some of the questions you might have on inclisiran and to help you feel prepared when talking to your patients about its initiation, we collected a list of answers to FAQs, available to download below. There, you will find useful information to understand the NHSE&I programme, plus practical answers relevant to your day-to-day practice, such as reimbursement information.

""

Download the patient identification infographic today,
and identify patients who could benefit from inclisiran

 

NICE recommends inclisiran as an option for treating adult patients within its licensed indication,1 who also have persistently elevated LDL-C levels (≥2.6 mmol/L despite maximum tolerated statins with or without ezetimibe, or other lipid-lowering therapies when statins are not tolerated or are contraindicated) and a history of certain cardiovascular events (acute coronary syndrome such as myocardial infarction or unstable angina needing hospitalisation, coronary or other arterial revascularisation procedures, coronary heart disease, ischaemic stroke or peripheral arterial disease).4

ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; FAQ, frequently asked question; HCP, healthcare professional; LDL-C, low-density lipoprotein cholesterol; NHS, National Health Service; NICE, National Institute for Health and Care Excellence

References

  1. Leqvio® Summary of Product Characteristics.
  2. Novartis. World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio®▼(inclisiran). Available at: https://www.novartis.com/news/media-releases/world-first-agreement-betwe.... [Accessed October 2021].
  3. NHS. Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of CVD. Available at: https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/04/Lipid.... [Accessed October 2021].
  4. NICE. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. Available at: https://www.nice.org.uk/guidance/ta733/resources/inclisiran-for-treating... [Accessed October 2021].
Rate this content: 
No votes yet
UK | November 2021 | 164224
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]